Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Multiple Myeloma 25Leukemia, Myeloid, Acute 24Lymphoma 22Breast Neoplasms 20Prostatic Neoplasms 15Colorectal Neoplasms 15Melanoma 14Leukemia, Lymphocytic, Chronic, B-Cell 14Lung Neoplasms 13Carcinoma, Non-Small-Cell Lung 13Neoplasm Metastasis 12Myelodysplastic Syndromes 12Lymphoma, Large B-Cell, Diffuse 12Squamous Cell Carcinoma of Head and Neck 11Pancreatic Neoplasms 11Ovarian Neoplasms 10Myeloproliferative Disorders 10Triple Negative Breast Neoplasms 8Rectal Neoplasms 8Leukemia, Myelomonocytic, Chronic 8Carcinoma, Renal Cell 8Burkitt Lymphoma 8Sarcoma 7Lymphoma, Follicular 7Colonic Neoplasms 7Urinary Bladder Neoplasms 6Lymphoma, Non-Hodgkin 6Glioma 6Fallopian Tube Neoplasms 6Cholangiocarcinoma 6

Interventions

tocotrienol, delta 1Surgical Procedures, Operative 1Sulindac 1Immunohistochemistry 1Erlotinib Hydrochloride 1Congresses as Topic 1Biopsy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Pancreatic Intraductal Neoplasms × Biopsy × Clear all
NCT00482625 2014-10-16

Erlotinib Hydrochloride in Treating Patients With Pancreatic Cancer That Can Be Removed by Surgery

National Cancer Institute (NCI)

Phase 2 Terminated
6 enrolled 8 charts
Gastrointestinal

Pancreatic Intraductal Neoplasms, Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡